Home / Market News / $MRK
benzinga Corporate Catalyst Impact 55/100 ● negative

Merck Discontinues Bacterial Infection Drug in Europe

Oct 20, 2026, 2:49 PM UTC · Primary ticker $MRK

Merck is discontinuing its bacterial infection therapy Zinplava (bezlotoxumab) in Europe and the US due to commercial reasons. This move, while indicating a lack of profitability for the drug, is unlikely to have a significant negative impact on Merck's overall financial performance given its broad portfolio and the stock's positive reaction.

Merck is discontinuing Zinplava, a drug for Clostridium difficile infection, in both Europe and the United States. The European Commission formally withdrew its marketing authorization at Merck's request, aligning with a planned US market exit in December 2024. This decision is driven by 'commercial reasons,' suggesting the drug did not meet profitability expectations. While the discontinuation of any drug is a negative event for that specific product, Zinplava was likely a small contributor to Merck's overall revenue given its broad and successful pharmaceutical portfolio. The stock's positive reaction on the day of the announcement suggests investors view this as a minor event, possibly even a positive in terms of resource reallocation, rather than a significant blow to the company's financials.

$MRK neutral Discontinuation of a drug for commercial reasons, minor impact on overall portfolio.
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.